Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБНУ «Научный центр психического здоровья». 115522, Россия, Москва, Каширское ш., д. 34
Список исп. литературыСкрыть список 1. Woodberry K, Shapiro D, Bryant C, Seidman L. Progress and future directions in research on the psychosis prodrome: A review for clinicians. Harv Rev Psychiatry 2016; 24 (2): 87–103. DOI: 10.1097/HRP.0000000000000109 2. Каледа В.Г., Мезенцева О.Е., Крылова Е.С., Бархатова А.Н. Особенности доманифестного этапа эндогенного психоза с первым приступом в юношеском возрасте. Журн. неврологии и психиатрии им. С.С.Корсакова. 2012; 112 (5): 22–8. / Kaleda V.G., Mezentseva O.E., Krylova E.S., Barkhatova A.N. Osobennosti domanifestnogo etapa endogennogo psikhoza s pervym pristupom v iunosheskom vozraste. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2012; 112 (5): 22–8. [in Russian] 3. Андриенко Е.В., Платонова Т.П., Тиганов А.С. Некоторые виды доманифестных расстройств при приступообразно-прогредиентной шизофрении. Журн. неврологии и психиатрии им. С.С.Корсакова. 2014; 114 (12): 31–5. DOI: 10.17116/jnevro201411412131-35 / Andrienko E.V., Platonova T.P., Tiganov A.S. Nekotorye vidy domanifestnykh rasstroistv pri pristupoobrazno-progredientnoi shizofrenii. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2014; 114 (12): 31–5. DOI: 10.17116/jnevro201411412131-35 [in Russian] 4. Коцюбинский А.П. Аутохтонные непсихотические расстройства. СПб.: СпецЛит, 2015. / Kotsiubinskii A.P. Autokhtonnye nepsikhoticheskie rasstroistva. SPb.: SpetsLit, 2015. [in Russian] 5. McGorry P, Yung A, Phillips L. The "close-in" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull 2003; 29: 771–90. DOI: http://dx.doi.org/10.1016/j.schres.2015.02.008 6. Miller T, McGlashan T, Woods S et al. Symptom assessment in schizophrenic prodromal states. Psychiatr Q 1999; 70: 273–87. 7. Омельченко М.А., Голубев С.А., Никифорова И.Ю., Каледа В.Г. Риск манифестации эндогенных психозов у больных с непсихотическими психическими расстройствами юношеского возраста. Журн. неврологии и психиатрии им. С.С.Корсакова. 2014; 114 (6): 14–20. / Omelchenko M.A., Golubev S.A., Nikiforova I.Iu., Kaleda V.G. Risk manifestatsii endogennykh psikhozov u bol'nykh s nepsikhoticheskimi psikhicheskimi rasstroistvami iunosheskogo vozrasta. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2014; 114 (6): 14–20. [in Russian] 8. Омельченко М.А., Румянцев А.О., Каледа В.Г. Динамика психопатологических симптомов ультравысокого риска манифестации шизофрении у больных с непсихотическими психическими расстройствами юношеского возраста. Журн. неврологии и психиатрии им. С.С.Корсакова. 2016; 116 (2): 16–21. DOI: 10.17116/jnevro20161162116-21 / Omelchenko M.A., Rumiantsev A.O., Kaleda V.G. Dinamika psikhopatologicheskikh simptomov ul'travysokogo riska manifestatsii shizofrenii u bol'nykh s nepsikhoticheskimi psikhicheskimi rasstroistvami iunosheskogo vozrasta. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2016; 116 (2): 16–21. DOI: 10.17116/jnevro20161162116-21 [in Russian] 9. Yung A, Yuen H, McGorry P et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psy-chiatry 2005; 39: 964–71. 10. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkotter J. Schizo-phrenia Proneness Instrument, Adult Version (SPI-A). Rome: Giovanni Fiority, 2007. 11. Thompson P, Cannon T, Narr K et al. Genetic influences on brain structure. Nat Neurosci 2001; 4: 1253–8. 12. Сергеева О.Е., Каледа В.Г., Голимбет В.Е. К вопросу о выявлении в подростково-юношеском возрасте группы высокого риска манифестации эндогенных психозов (психопатологические и молекулярно-генетические аспекты). Психиатрия. 2014; 3; 59–60. / Sergeeva O.E., Kaleda V.G., Golimbet V.E. K voprosu o vyiavlenii v podrostkovo-iunosheskom vozraste gruppy vysokogo riska manifestatsii endogennykh psikhozov (psikhopatologicheskie i molekuliarno-geneticheskie aspekty). Psikhiatriia. 2014; 3; 59–60. [in Russian] 13. Fusar-Poli P, Deste G, Smieskova R et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 2012: 69 (3): 1–10. DOI: 10.1001/archgenpsychiatry.2011.1592 14. Dickson H, Laurens K, Cullen A, Hodgins S. Meta-analyses of cognitive and motor function in youth aged 16 and younger who subsequently developed schizophrenia. Psychol Med 2011; 42: 743–55. DOI: 10.1017/S0033291711001693 15. Guiliano A, Mesholam-Gately R, Sorenson S et al. Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr Pharm Des 2012; 18: 399–415. DOI: 10.2174/ 138161212799316019 16. Steullet P, Cabungcal J, Monin A et al. Redox disregulation, neuroinflammation, and NMDA receptor hypofunction: a "central hub" in schizophrenia pathophysiology? Schizophr Res 2014. DOI: 10.1016/ j.schres.2014.06.021 17. Perkins D, Jeffries C, Addington J et al. Toward a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary result from the NAPLS project. Schizophr Bull 2015; 41: 419–28. DOI: 10.1093/schbul/sbu099 18. Thermenos H, Keshavan M, Juelich R et al. A review of neuroimaging studies of young relatives of persons with schizophrenia: a developmental perspective from schizotaxia to schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2013; 162: 604–35. DOI: 10.1002/ ajmg.b.32170 19. Лебедева И.С., Каледа В.Г., Абрамова Л.И. и др. Нейрофизиологические аномалии в парадигме Р300 как эндофенотипы шизофрении. Журн. неврологии и психиатрии им. С.С.Корсакова. 2008; 1: 61–70. / Lebedeva I.S., Kaleda V.G., Abramova L.I. i dr. Neirofiziologicheskie anomalii v paradigme R300 kak endofenotipy shizofrenii. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2008; 1: 61–70. [in Russian] 20. Brent B, Thermenos H, Keshavan M, Seidman L. Gray matter alterations in schizophrenia high-risk youth and early-onset schizophrenia: a review of structural MRI findings. Child Adolesc Psychiatr Clin N Am 2013; 22: 689–714. DOI: 10.1016/j.chc.2013.06.003 21. Walker E, Brennan P, Esterberg M et al. Longitudinal changes in cortisol secretion and conversion to psychosis in at-risk youth. J Abnorm Psychol 2010; 119: 401–8. DOI: 10.1037/a0018399 22. Tienari P, Wynne L, Sorri A et al. Genotype-environment interaction in schizophrenia-spectrum disorder long-term follow-up study of Finnish adoptees. Br J Psychiatry 2004; 184: 216–22. 23. Gogos A, Sbisa A, Sun J et al. A role for estrogen in schizophrenia: clinical and preclinical findings. Int J Endocrinol 2015; 2015: 615356. DOI: 10.1155/2015/615356 24. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: The basic symptom concept. Schizophr Bull 2009; 35 (1): 5–8. DOI:10.1093/schbul/sbn139 25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Publishing, 2013. 26. Fusar-Poli P, Bonoldi I, Yung A et al. Prediction psychosis: meta-analysis of transition outcome in individuals at high clinical risk. Arch Gen Psychiatry. 2012; 69 (3): 220–9. DOI:10.1001/archgenpsychiatry.2011.1472 27. Simon A, Velthorst E, Nieman D et al. Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res 2011; 132 (1): 8–17. DOI:10.1016/j.schres.2011.07.002 28. Cooper C, Morgan C, Byrne M et al. Perception of disadvantage, ethnicity and psychosis. Br J Psychiatry 2008; 192 (3): 185–90. DOI: 10.1192/bjp.bp.107.042291 29. Goldstein J, Buka S, Seidman L, Tsuang M. Specificity of familial transmission of schizophrenia psychosis spectrum and affective psychoses in the New England family study's high-risk design. Arch Gen Psychiatry 2010; 67 (5): 458–67. DOI: 10.1001/archgenpsychiatry.2010.38 30. Brown A. The environment and susceptibility to schizophrenia. Prog Neurobiol 2011; 93: 23–58. DOI: 10.1016/j.pneurobio.2010.09.003 31. Gururajan A, Manning E, Klug M, van der Buuse M. Drugs of abuse and increase risk of psychosis development. Aust N Z J Psychiatry 2012; 46: 1120–35. DOI: 10.1177/0004867412455232 32. Clark S, Schubert K, Baune B. Towards indicated prevention of psychosis: using probabilistic assessments of transition risk in psychosis prodrome. J Neural Transm (Vienna) 2015; 122: 155–69. DOI: 10.1007/s00702-014-1325-9 33. Лутова Н.Б., Борцов А.В., Вукс А.Я., Вид В.Д. Метод прогнозирования медикаментозного комплайенса в психиатрии: методические рекомендации. СПб.: НИПНИ им. В.М.Бехтерева, 2007. / Lutova N.B., Bortsov A.V., Vuks A.Ia., Vid V.D. Metod prognozirovaniia medikamentoznogo komplaiensa v psikhiatrii: metodicheskie rekomendatsii. SPb.: NIPNI im. V.M.Bekhtereva, 2007. [in Russian] 34. Addington J, Cornblatt B, Cadenhead K et al. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychistry 2011; 168 (8): 800–5. DOI.org/10.1176/appi.ajp.2011.10081191 35. Schmidt S, Schultze-Lutter F, Schimmelmann B et al. EPA guidance on the early interention in clinical high risk states of psychosis. Eur Psy-chiatry 2015; 30: 388–404. DOI: 10.1016/j.eurpsy.2015.01.013 36. Heinssen R, Insel T. Preventing the onset of psychosis: not quite there yet. Schizophr Bull 2015; 41: 28–9. DOI: 10.1093/schbul/sbu161 37. Berger G, Wood S, Ross M et al. Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Curr Pharm Des 2012; 18 (4): 570–5. 38. Woods S, Walsh B, Hawkins K et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol 2013; 23: 931–40. DOI: 10.1016/j.euroneuro.2012. 09.008 39. Kantrowits J, Woods S, Petkova E et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry 2015; 2: 403–12. DOI: 10.1016/S2215-0366(15)00098-X 40. Amminger G, Schafer M, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67 (2): 146–54. DOI: 10.1001/archgenpsychiatry.2009.192 41. Nordentoft M, Thorup A, Petersen L et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 2013; 148: 99–104. 42. Woods S, Addington J, Cadenhead K et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull 2009; 35: 894–908. DOI: 10.1093/schbul/sbp027 43. Fusar-Poli P, Borgwardt S, Bechdolf A et al. The Psychosis High-Risk State. JAMA Psychiatry 2013; 70 (1): 107–20. DOI: 10.1001/jamapsychiatry.2013.269 44. Cornblatt B, Carrión R, Addington J et al. Risk factors for psychosis: impaired social and role functioning. Shizophr Bull 2012; 38 (6): 1247–57. DOI: 10.1093/schbul/sbr136 45. Van der Gaag M, Smit F, Bechdolf A et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 months and longer-term follow-ups. Schizophr Res 2013; 149: 56–62. DOI: 10.1016/j.schres.2013.07.004